multiple myeloma
Conditions
Interventions
Experimental group:chidamide combined with ixazomib, cyclophosphamide, and dexamethasone
Sponsors
Union Hospital Fujian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with active multiple myeloma, relapse after initial treatment remission, failure or progression after second-line or above, including autologous stem cell transplantation; 2. Secretory multiple myeloma, with measurable indicators; 3. Aged above 18 years, no gender limit; 4. General body condition score ECOG 0-2, expected to survive more than 3 months; 5. Serum liver enzyme value =1.5x10^9/L, platelet count >=50x10^9/L, glomerular filtration rate (eGFR) >=50mL/ min; 6. Left ventricular ejection fraction was normal with no obvious cardiac or pulmonary dysfunction (<=I degree); 7. Can accept adverse reactions and efficacy observation according to the requirements of the experiment; 8. The patient must be able to understand and voluntarily sign the informed consent, which must be signed prior to any trial procedure.
Exclusion criteria
Exclusion criteria: 1. Lesions of extramedullary plasma cells; 2. Patients with grade 3 or above peripheral neuropathy at the time of enrollment; 3. Those who are being treated with other effective programmes; 4. Pregnant and lactating patients; 5. Allergic constitution, such as allergic history of two or more drugs or food; Or known allergy to the drug component; 6. Patients suffering from uncontrollable mental illness; 7. Patients with active infection; 8. There are situations that other researchers think are not suitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate, ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free Survival, PFS;Duration of Response, DOR;Safety; | — |
Countries
China
Contacts
Public ContactXu Zhenshu
Union Hospital Fujian Medical Hospital
Outcome results
None listed